MONTEROSA - Italian Multicenter Observational Study to Evaluate Time to Clinical Hepatic Decompensation, Quality of Life, Effectiveness, and Safety of Tremelimumab Plus Durvalumab in Patients With Advanced or Unresectable Hepatocellular Carcinoma Who Have Received no Prior Systemic Treatment.

MONTEROSA Italian Multicenter Observational Study to Evaluate Time to Clinical Hepatic Decompensation, Quality of Life, Effectiveness, and Safety of Tremelimumab Plus Durvalumab in Patients With Advanced or Unresectable Hepatocellular Carcinoma Who Have Received no Prior Systemic Treatment. (Real World Observational Study of STRIDE Regimen for Advanced HCC)

Italian multicenter observational study to evaluate time to clinical hepatic decompensation, quality of life, effectiveness, and safety of tremelimumab plus durvalumab in patients with advanced or unresectable hepatocellular carcinoma who have received no prior systemic treatment.

Inclusion Criteria:

• - Signed informed consent.
• Age ≥ 18 years.
• Histologically or radiologically confirmed diagnosis of advanced or unresectable HCC.
• BCLC B or C HCC.
• Child-Pugh A (score 5 or 6).
• Eastern Cooperative Oncology Group (ECOG) Performance Status score 0 or 1.
• Planned first-line treatment of advanced/uHCC with STRIDE.

Exclusion Criteria:

• - Any previous line of systemic therapy for HCC.
• Any prior or concomitant immunotherapy.
• Prior allogeneic organ or bone marrow transplant.
• Documented active or previous GI bleeding within the previous 12 months.
• Main trunk portal vein thrombosis.
• Autoimmune disease requiring treatment with immunosuppressive medication.
• Known hypersensitivity to the active substance or to any of the STRIDE excipients.
• Pregnancy or breastfeeding